Above and Beyond

What Above and Beyond does

Above and Beyond Concierge Therapeutics is a privately held precision medicine company founded in 2014 and headquartered in Atlanta, Georgia, that focuses on nervous system disorders, primarily amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions for which there is no cure. The company combines hyper-personalized diagnostics (advanced genetic screening, biomarker assays, and patient-derived iPSC stem cell manipulation) with novel individuated therapies (FDA-approved drug repurposing, tailored gene therapies, intrathecal drug delivery, and access to investigational drugs) and neural augmentation approaches including brain-computer interfaces. A flagship research program involves a novel proprietary intrathecal formulation of riluzole (use patent pending, Application No. 15/664,937) demonstrated to achieve up to a 10-fold increase in spinal cord drug concentration versus oral administration, with a Phase 1 IND trial planned. The company also pursues patient-specific gene therapy (iPSC-derived motor neurons) and a Neuromuscular Restoration Program aimed at rebuilding neuromuscular junctions and motor function.

The firm operates as a concierge precision medicine provider on a professional services basis, recruiting a personalized multidisciplinary Scientific Advisory Board for each patient and enabling patients to choose which therapeutic research programs to fund. Go-to-market combines direct engagement with patients who have incurable neurodegenerative diseases with a concierge physician/clinician referral model, supplemented by industry summits (e.g., the July 2018 Manhattan Neuromuscular Restoration Summit) for thought leadership. Strategic partnerships extend the technical platform: AcuraStem provides patient-derived motor neuron drug screening, Icagen validates sporadic ALS mutations, Insilico Medicine applies its ALS.AI deep learning platform to the company's transcriptomic data for target and biomarker discovery, Medtronic supplies Synchromom II pumps and Ascenda catheters for intrathecal delivery research, and Collaborative Medicinal Development provides access to clinical-stage ALS assets such as CuATSM.

The company is founder-led by Nicholas M. Boulis, MD (Emory University, 100+ peer-reviewed publications, 4 patents) as Founder and Scientific Advisory Chair, with Chen Benkler, PhD as Chief Scientific Officer. With only 1-10 employees and no disclosed institutional funding, the business is structurally a boutique precision medicine practice that leverages external partnerships to extend its R&D capacity. Notable milestones include the identification of a novel M1311V ATP7A mutation in an ALS patient through whole genome sequencing and cell modeling, and progression of intrathecal riluzole and gene therapy programs toward IND-enabling studies.

Name

Above and Beyond

Legal name

Above and Beyond Concierge Therapeutics

Website

https://aboveandbeyond-ct.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Above and Beyond Concierge Therapeutics is an Atlanta-based precision medicine company that delivers hyper-personalized diagnostics, drug repurposing, gene therapy, and neural augmentation services to individual patients with incurable neurodegenerative diseases, primarily ALS.

Ownership category

akta.pro rank

Product category

Precision Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Neuromuscular Medicine (ALS, Myasthenia, Neuropathy) (HLAKAIAD), Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Precision medicine services
• Personalized diagnostics
• Neurodegenerative therapies
• Concierge therapeutics
• Gene therapy research

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Concierge Precision Medicine Services: Above and Beyond provides personalized therapeutic-oriented research and novel therapeutic intervention development for persons with incurable disease. The company assembles personalized Scientific Advisory Boards for each patient, with patients choosing which programs to fund. Revenue appears to come from service fees for personalized research programs and therapeutic development services.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Above and Beyond Concierge Therapeutics delivers highly personalized therapeutic-oriented research combined with discovery and testing of novel therapeutic interventions at an accelerated pace for persons with incurable disease, primarily ALS and other neurodegenerative conditions. Each patient receives a dedicated clinical/research team, a customized care plan, and a personalized Scientific Advisory Board of field experts assembled to evaluate options beyond standard of care. The offering spans hyper-personalized diagnostics (genetic screening, biomarker assays, patient stem cell manipulation), novel individuated therapies (FDA-approved drug repurposing, tailored gene therapies, access to investigational drugs), and neural augmentation (brain-computer interfaces and advanced sensor techniques).

Product overview

Above and Beyond Concierge Therapeutics operates as a precision medicine company offering a suite of personalized healthcare services rather than a traditional product portfolio. The company provides hyper-personalized diagnostics (including genetic screening, biomarker assays, and patient stem cell manipulation), individuated therapeutic development (FDA-approved drug repurposing, tailored gene therapies, access to investigational drugs), and neural augmentation services (brain-computer interfaces, restorative approaches). Each patient receives a customized Scientific Advisory Board of field experts. The company focuses on patients with incurable conditions, particularly ALS and neurodegenerative diseases, targeting functional restoration rather than just disease slowing.

Differentiator

Problem solved

Functional benefit

Products and services

• Personalized Diagnostics Services

Quantifiable outcome

• Ten-fold increase in spinal cord riluzole concentration compared to oral administration
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• AcuraStemcoreStrategic or Co-development PartnerAcuraStem, formed in 2016 and headquartered in Monrovia, California, is a precision medicine platform addressing ALS. They use ALS-patient stem cells and advanced machine-learning technology to create cellular models and assays. AcuraStem entered into an agreement with Above and Beyond to profile FDA approved drugs on a patient's living motor neurons, supporting A&B's precision medicine program.
• IcagencoreStrategic or Co-development PartnerIcagen, headquartered in Oro Valley, Arizona, is an integrated early discovery partner offering specialized technologies and deep scientific expertise. They collaborated with Above and Beyond on the validation of mutations that cause a spontaneous form of ALS, contributing to A&B's approach to addressing genetic causes of sporadic ALS and identifying individualized treatments.
• Insilico MedicinecoreTechnology or IntegrationInsilico Medicine, headquartered near Baltimore on the campus of Johns Hopkins University, develops AI solutions for drug discovery, personalized healthcare, and anti-aging. In 2015, Above and Beyond engaged Insilico on a comprehensive target discovery and small molecule scoring project. A&B provided transcriptomic data from ALS patients for analysis by Insilico's ALS.AI platform using deep learning to identify personalized drugs and biomarkers.
• Collaborative Medicinal Development LLCminorStrategic or Co-development PartnerCollaborative Medicinal Development LLC, with U.S. headquarters in Sausalito, California, focuses on cancer and neurodegenerative diseases. They pursue clinical trials of promising drugs including CuATSM, a small synthetic copper-containing molecule being tested in ALS patients since 2016.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• BrainStorm Cell Therapeutics: Cell-therapy biotech developing autologous MSC-NTF cells for ALS; broad incumbent using intrathecal cell delivery for motor neuron disease, technically and indication-adjacent.
• Biogen: Large CNS-focused biotech with approved ALS therapy (Radicava/QAIS) and an active neurodegenerative pipeline; broad incumbent competing for the same ALS patient population and CNS clinical real estate.
• Cytokinetics: Specialty cardiovascular and neuromuscular biopharma with late-stage ALS programs (e.g., reldesemtiv); broad incumbent with deep neuromuscular drug-development expertise relevant to Above and Beyond's IND direction.
• bluebird bio: Established gene and cell therapy company; connection is reinforced by Above and Beyond's business development lead Cyrus Moazzeni, a former VP/global head of BD at bluebird bio; broad incumbent in personalized genetic medicines.
• uniQure: Late-stage gene therapy company with AAV manufacturing, CNS delivery expertise and an active ALS program; broad incumbent in CNS gene therapy platforms.
• AveXis / Novartis Gene Therapies: Approved Zolgensma for SMA via intrathecal/IV AAV gene therapy; broad incumbent in CNS gene therapy with the device, manufacturing and regulatory infrastructure Above and Beyond is approaching with intrathecal riluzole.

Emerging players

• Insilico Medicine: AI drug-discovery platform with dedicated ALS.AI offering developed in collaboration with Above and Beyond; emerging player in deep-learning-driven neurodegenerative target discovery and biomarker identification.
• Lexeo Therapeutics: Clinical-stage gene therapy company focused on CNS diseases including APOE4-associated Alzheimer's; emerging player in CNS-targeted AAV gene therapy pursuing a similar patient-tailored regulatory path.
• Passage Bio: Clinical-stage AAV gene therapy company targeting rare monogenic CNS disorders; emerging player using intrathecal AAV delivery with similar device and regulatory approach.

Direct peers

• AcuraStem: Precision medicine platform for ALS using patient stem cells and ML to build cellular models; already a co-development partner of Above and Beyond doing drug profiling on patient motor neurons, making it the most direct comparable.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AboveBeyond_CT
• LinkedInlinkedin.com/company/above-and-beyond-concierge-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Above and Beyond